|
KMID : 1007020090070010001
|
|
Korean Soceity of Osteroporosis
2009 Volume.7 No. 1 p.1 ~ p.5
|
|
|
Bisposphonates and Osteoporosis
|
|
Lee Hae-Hyeog
|
|
|
Abstract
|
|
|
|
The bisphosphonate class of drugs act to inhibit bone resorption by interfering with the activity of osteoclasts. Bisphosphonate was developed and marketed as an intervention to reduce vertebral and nonvertebral fractures in postmenopausal women. Bisphosphonate associated osteonecrosis of jaw (ONJ) is associated with high-dose bisphosphonate therapy primarily in the oncology patient population. Prevention and treatment strategies are currently based on expert opinion and focus on maintaining good oral hygiene and conservative surgical intervention. Currently, four bisphosphonates, 1) alendronate, 2) risedronate, 3) ibandronate, and 4) zoledronic acid, are approved in the United States. Alendronate, risedronate and ibandronate are oral agents, and ibandronate and zoledronic acid are intravenous drugs.
|
|
|
KEYWORD
|
|
|
Bisphosphonate, Osteoporosis, Menopause
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|